Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients

We conducted a retrospective study of the case files of 64 multiple sclerosis (MS) patients presenting severe spasticity, who had received intrathecal (IT) baclofen test injections between 1992 and 2004 in a rehabilitation unit. In almost all cases of our series, IT baclofen was proposed to patients...

Full description

Saved in:
Bibliographic Details
Published inMultiple sclerosis Vol. 12; no. 1; pp. 101 - 3
Main Authors Ben Smail, D., Peskine, Anne, Roche, Nicolas, Mailhan, L., Thiébaut, I- B, Bussel, B.
Format Journal Article
LanguageEnglish
Published SAGE Publications 01.02.2006
Subjects
Adult
Aged
Animal biology
Baclofen
Disabled Persons
Humans
Injections, Spinal
Life Sciences
Middle Aged
Multiple Sclerosis
Muscle Relaxants, Central
Muscle Spasticity
Retrospective Studies
Time Factors
Treatment Outcome
Veterinary medicine and animal Health
Online AccessGet full text

Cover

More Information
Summary:We conducted a retrospective study of the case files of 64 multiple sclerosis (MS) patients presenting severe spasticity, who had received intrathecal (IT) baclofen test injections between 1992 and 2004 in a rehabilitation unit. In almost all cases of our series, IT baclofen was proposed to patients who were no longer able to walk. IT baclofen is a safe and effective treatment to reduce spasticity in MS patients. Despite an advanced stage of the disease at the time of pump placement, the complication rate was low and the efficacy of this treatment was maintained over time.
ISSN:1352-4585
1477-0970